CN1105236A - Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof - Google Patents
Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof Download PDFInfo
- Publication number
- CN1105236A CN1105236A CN 93114694 CN93114694A CN1105236A CN 1105236 A CN1105236 A CN 1105236A CN 93114694 CN93114694 CN 93114694 CN 93114694 A CN93114694 A CN 93114694A CN 1105236 A CN1105236 A CN 1105236A
- Authority
- CN
- China
- Prior art keywords
- aerosol
- sodium
- preventing transmission
- treatment
- propellant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 43
- 208000008128 pulmonary tuberculosis Diseases 0.000 title claims abstract description 20
- 230000005540 biological transmission Effects 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 9
- 239000003814 drug Substances 0.000 claims description 18
- 239000003380 propellant Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 210000004907 gland Anatomy 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
- 239000004338 Dichlorodifluoromethane Substances 0.000 claims description 6
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 6
- 235000019404 dichlorodifluoromethane Nutrition 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 5
- 239000000375 suspending agent Substances 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 4
- AUAHHJJRFHRVPV-BZDVOYDHSA-N ethambutol dihydrochloride Chemical compound [Cl-].[Cl-].CC[C@@H](CO)[NH2+]CC[NH2+][C@@H](CC)CO AUAHHJJRFHRVPV-BZDVOYDHSA-N 0.000 claims description 4
- -1 fluorine alkyl chloride chemical compound Chemical class 0.000 claims description 4
- PPGHYTPFGILTSZ-PPJQWWMSSA-M gpe7477yek Chemical compound [Na+].O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C([O-])C=2\C=N\N1CCN(C)CC1 PPGHYTPFGILTSZ-PPJQWWMSSA-M 0.000 claims description 4
- XIKFVJMQXWJVQW-UHFFFAOYSA-M sodium;[2-(pyridine-4-carbonyl)hydrazinyl]methanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CNNC(=O)C1=CC=NC=C1 XIKFVJMQXWJVQW-UHFFFAOYSA-M 0.000 claims description 4
- 229960005322 streptomycin Drugs 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 claims description 2
- FVVDKUPCWXUVNP-UHFFFAOYSA-M Aminosalicylate sodium anhydrous Chemical compound [Na+].NC1=CC=C(C([O-])=O)C(O)=C1 FVVDKUPCWXUVNP-UHFFFAOYSA-M 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 235000021050 feed intake Nutrition 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 229960003350 isoniazid Drugs 0.000 claims description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000001272 nitrous oxide Substances 0.000 claims description 2
- TWZDRYOVRLCSPI-UHFFFAOYSA-N pyrazine-2-carboxamide;hydrochloride Chemical compound Cl.NC(=O)C1=CN=CC=N1 TWZDRYOVRLCSPI-UHFFFAOYSA-N 0.000 claims description 2
- AWUDMMYDVXKZFX-WRCDTYNQSA-N rifamdin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C)/C(=O)NC2=C(O)C=3C(O)=C4C)C)OC)C4=C1C=3C(=O)\C2=C\NN1CCN(CC(C)C)CC1 AWUDMMYDVXKZFX-WRCDTYNQSA-N 0.000 claims description 2
- XUBKCCSAVNRWOX-BVHPQESASA-N rifandin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2N1CCN(CC(C)C)CC1 XUBKCCSAVNRWOX-BVHPQESASA-N 0.000 claims description 2
- 229940046927 sodium aminosalicylate Drugs 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- 239000000814 tuberculostatic agent Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000001856 aerosol method Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The aerosol for preventing the transmission of and curing lung tuberculosis features its atomizing application to create a new way of administration.
Description
The invention belongs to a kind of pharmaceutical preparation and preparation method.
Public media and clinical report repeatedly once in recent years, pulmonary tuberculosis is trend occurred frequently in recent years in worldwide, submit to the public to improve control lungy consciousness whereby.At present the anti-tuberculosis drugs of using clinically mainly is by oral or inject two administrations.Because the restriction of the property of medicine, antibacterial characteristic and route of administration occurs then involving relevant internal organs when dosage is big often, and toxigenicity; Dosage hour then brings out antibacterial and produces Resistant strain and drug resistance occurs, thereby give clinical treatment lungy, bring very burden, forward attention to atomizing suction topical for addressing the above problem the existing medical worker of part, in the hope of improving the drug level of lesions position, reduce the medication total amount, reduce toxicity.As " clinical medicine " 1989,9(5)-two attached institutes of 205-206 Xinxiang College of Medical Science, ultrasonic atomizatios such as Liu Duowu suction antituberculosis drugs is treated long-term discharge of bacteria pulmonary tuberculosis 38 examples and is gain the curative effect of making us inspiring very much happily; " Chinese Hospitals pharmaceutical journal " 1983,3(2)-5-7, the rifampicin powder aerosol clinical practice curative effect of developments such as Shanghai City Luwan District central hospital soup state post also belongs to superior; " pharmacy circular " 1980,15(8)-15 Qiao Zhang of Pharmacy department of Suzhou City's infectious disease tuberculosis hospital star trial-production and the streptomycin powder aerosol used, its clinical practice also obtains gratifying result, but as if the angle from pharmaceutics and industrialized great production, above-mentioned three examples all have deficiency separately.Ultrasonic atomizatio inhalation apparatus cost is too high, so can only carry out in hospital, can not enter huge numbers of families, is unsuitable for extensive patients and carries use; The rifampicin powder aerosol, because isceon and dichlorodifluoromethane in the prescription all have certain dissolubility to the crude drug rifampicin, simultaneously again owing to do not add in the prescription of this aerosol and do not make a gesture of measuring regulator, so this aerosol is placed and is produced recrystallization after a period of time and make partially crystallizable become big and the granule come-up is inter-adhesive and to block shower nozzle be inevitable thing; There is not adding to be difficult to be adapted to industrialized great production in the prescription of streptomycin powder aerosol for the ease of the dosage control that packing increases volumetrical latent solvent matchmaker isceon so that packing operation, simultaneously owing to do not add the proportion regulator in the prescription yet, therefore be directed at aerosol too and placed granule come-up after a period of time, inter-adhesive and phenomenon that block shower nozzle takes place.Medicine also is difficult to enter pulmonary under this granularity simultaneously.
But the objective of the invention is provides the pulmonary tuberculosis preventing transmission of the direct administration of focus and treatment with aerosol and preparation method thereof some antitubercular agent being modified on the salifiable basis to society.
Pulmonary tuberculosis preventing transmission of the present invention and treatment can be divided into two kinds of solution-type and suspension types with aerosol, now state as follows:
Solution-type pulmonary tuberculosis preventing transmission and treatment are by medicine with aerosol; Formations such as latent solvent matchmaker, propellant, its Chinese medicine is optional; Should account for the 1-22% of aerosol total amount with wherein at least a its consumptions such as ebutol, Tuborin, rifampicin sodium, rifandin sodium, R-77-3 sodium; The optional water of latent solvent matchmaker, ethanol, propylene glycol, dimethyl sulfoxide etc. are wherein at least a, and its consumption should account for the 10-90% of aerosol total amount; Propellant can be selected compressed air for use, nitrous oxide, nitrogen, carbon dioxide, and liquid gas, Hydrocarbon, fluorine alkyl chloride chemical compounds etc. are wherein at least a, and its consumption should account for the 10-30% of aerosol total amount.Its preparation method is by feeding intake, adjusts, and check, packing, charges into several procedures such as propellant and finishes at gland.
Suspension type pulmonary tuberculosis preventing transmission and treatment are to be made of with latent solvent matchmaker, propellant etc. medicine, proportion regulator, suspending agent, increase volume with aerosol, the optional 2-22% that should account for the aerosol total amount with wherein at least a its consumptions such as sodium isonicotinylhydrazide methanesulfonate, hydrochloric acid isoniazid, hydrochloric acid pyrazinamide, ebutol, rifampicin sodium, rifamdin sodium, R-77-3 sodium streptomycin, sodium aminosalicylate of its Chinese medicine; The 0-20% suspending agent that the proportion regulator can select for use anhydrous sodium sulfate or its consumption of Lactis Anhydrous should account for the aerosol total amount can be selected Arlacel-85 or ethyl oleate for use, and its consumption should account for the 1-20% of aerosol total amount; The latent solvent matchmaker can select isceon or vegetable oil for use, and its consumption should account for the 10-50% of aerosol total amount; Propellant can be selected dichlorodifluoromethane or dichlorotetra-fluoroethane for use, and its consumption should account for the 40-80% of aerosol total amount.Its preparation method is by pulverizing, feed intake, adjustment, packing, gland, charging into several procedures such as propellant and finish.
Aerosol is used in pulmonary tuberculosis preventing transmission that the present invention produces and treatment, is another route of administration of antitubercular agent.But this preparation is compared the direct administration of its indication pulmonary tuberculosis focus, or injection oral with traditional route of administration of antitubercular agent, and it is little to have an overall dosage, local lesion's drug level height, the curative effect height, instant effect, toxic and side effects is little, but the painless characteristics of waiting bitterly for of patient's self-administration.Again because aerosol is the pulmonary administration by respiratory tract, medicine that respiratory tract is remaining and respiratory tract progressively on the sputum that moves time enough is arranged, the space fully contacts, tubercule bacillus number in the sputum of patient's expectoration is reduced rapidly or disappear, thereby to controlling phthisical propagation and phthisical control has certain positive effect.
For the present invention is further illustrated, provide the preparation method of following embodiment 1, solution-type Tuborin aerosol: prescription: Tuborin 75g, propylene glycol 25g, ethanol 460g, dichlorodifluoromethane 350g.Method for making: in the ethanol that is equivalent to 3/4 amount that Tuborin is dissolved in, add propylene glycol then, to capacity, filter, after the assay was approved, be sub-packed in 100 bottles, gland, charge into the 3.5g dichlorodifluoromethane promptly by every bottle on valve on the lid with ethanol dilution.
The preparation method of embodiment 2, suspension type sodium isonicotinylhydrazide methanesulfonate aerosol, learn from else's experience sodium isonicotinylhydrazide methanesulfonate 50g, anhydrous sodium sulfate 45g below 5 μ m of the particle diameter pulverized by jet mill, with the 42g Arlacel-85 with placing newborn body to grind evenly, add the 400g Dichloromonofluoromethane and grind to form homogenate, and move in the adjustment cylinder, stir, after the assay was approved, be sub-packed in 100 aluminum Room bottles, gland also charges into the 9g dichlorodifluoromethane promptly by every bottle on valve on the lid.
Claims (9)
1, a kind of solution-type pulmonary tuberculosis preventing transmission and treatment aerosol, it is characterized in that this aerosol is to be made of medicine, latent solvent matchmaker, propellant etc., its Chinese medicine is optional wherein at least a with ebutol, Tuborin, rifampicin sodium, rifandin sodium, R-77-3 sodium etc.; The optional water of latent solvent matchmaker, ethanol, propylene glycol, dimethyl sulfoxide etc. are wherein at least a; Propellant can select for use compressed air carbon dioxide, nitrous oxide, nitrogen, liquid gas, Hydrocarbon, fluorine alkyl chloride chemical compound etc. wherein at least a.
2, pulmonary tuberculosis preventing transmission as claimed in claim 1 and treatment aerosol, the percentage ratio that it is characterized in that constituting each ingredients constitute aerosol content total amount of aerosol content is medicine 1-22%, latent solvent matchmaker 10-90% propellant 10-80%.
3, aerosol is used in a kind of solution-type pulmonary tuberculosis preventing transmission and treatment, it is characterized in that this aerosol is by feeding intake, adjust, check, packing, gland, charging into several procedures such as propellant and finish.
4, a kind of suspension type pulmonary tuberculosis preventing transmission and treatment aerosol, the content that it is characterized in that this aerosol is to be made of medicine, proportion regulator, suspending agent, latent solvent matchmaker, propellant etc., its Chinese medicine is optional with sodium isonicotinylhydrazide methanesulfonate, hydrochloric acid isoniazid, hydrochloric acid pyrazinamide, ebutol, rifampicin sodium, rifamdin sodium, R-77-3 sodium, streptomycin, and sodium aminosalicylate etc. are wherein at least a; The proportion regulator can be selected anhydrous sodium sulfate or Lactis Anhydrous for use; Suspending agent can be selected Arlacel-85 for use, or ethyl oleate; The latent solvent matchmaker can select isceon or vegetable oil for use; Propellant can be selected dichlorodifluoromethane or dichlorotetra-fluoroethane for use.
5, aerosol is used in suspension type pulmonary tuberculosis preventing transmission as claimed in claim 4 and treatment, and the percentage ratio that it is characterized in that constituting each ingredients constitute aerosol content total amount of this aerosol content is total thing 2-22%; Proportion regulator 0-20%; Suspending agent 1-20%; Latent solvent matchmaker 10-50%; Propellant 40-80%.
6, aerosol use in a kind of suspension type pulmonary tuberculosis preventing transmission and treatment, it is characterized in that this aerosol is by pulverizing, feeds intake, adjustment, packing, gland, charges into several procedures such as propellant and finish.
7, suspension type pulmonary tuberculosis preventing transmission as claimed in claim 6 and treatment be with the preparation method of aerosol, and no matter the solid drugs and the proportion regulator of the usefulness that it is characterized in that feeding intake via which kind of grinding mode are pulverized, and its granularity must reach below the 10 μ m.
8, suspension type pulmonary tuberculosis preventing transmission as claimed in claim 6 and treatment be with the preparation method of aerosol, it is characterized in that adjusting, packing, gland, etc. the temperature of three process operating system must be controlled at below 23 ℃.
9, suspension type pulmonary tuberculosis preventing transmission as claimed in claim 6 and treatment aerosol, it is characterized in that pulverizing, the measure that feed intake, several procedures such as adjustment, packing, gland and all raw material, adjuvants all should be taked strict control moisture, the finished product water content should be controlled at below the 300ppm.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93114694 CN1105236A (en) | 1993-11-13 | 1993-11-13 | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof |
| CN 94104237 CN1134278A (en) | 1993-11-13 | 1994-04-24 | Aerosol for preventing and curing pulmonary tuberculosis and its preparing method and synergy method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93114694 CN1105236A (en) | 1993-11-13 | 1993-11-13 | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1105236A true CN1105236A (en) | 1995-07-19 |
Family
ID=4990607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 93114694 Pending CN1105236A (en) | 1993-11-13 | 1993-11-13 | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1105236A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102413837A (en) * | 2009-04-24 | 2012-04-11 | 国立血清研究所 | TB vaccine against reactivated tuberculosis |
| CN105025921A (en) * | 2013-03-15 | 2015-11-04 | 宾夕法尼亚大学理事会 | Synthetic immunogens for the prevention or treatment of tuberculosis |
-
1993
- 1993-11-13 CN CN 93114694 patent/CN1105236A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102413837A (en) * | 2009-04-24 | 2012-04-11 | 国立血清研究所 | TB vaccine against reactivated tuberculosis |
| CN102413837B (en) * | 2009-04-24 | 2015-11-25 | 国立血清研究所 | TB vaccine against reactivated tuberculosis |
| CN105025921A (en) * | 2013-03-15 | 2015-11-04 | 宾夕法尼亚大学理事会 | Synthetic immunogens for the prevention or treatment of tuberculosis |
| CN105025921B (en) * | 2013-03-15 | 2019-02-19 | 宾夕法尼亚大学理事会 | Synthetic immunogens for the prevention or treatment of tuberculosis |
| US10953079B2 (en) | 2013-03-15 | 2021-03-23 | The Trustees Of The University Of Pennsylvania | Synthetic immunogens for prophylaxis or treatment of tuberculosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101069675A (en) | A method of alleviating signs and symptons of spasticity | |
| JPH03167119A (en) | Pharmaceuticals | |
| CN106667975A (en) | Preparation method of ipratropium bromide solution for inhalation | |
| WO2022116792A1 (en) | Isoniazid dry powder inhalant for treating pulmonary tuberculosis | |
| CN116159052A (en) | Combined application, pharmaceutical composition and application thereof | |
| Sivak et al. | Management of hypoventilation in motor neuron disease presenting with respiratory insufficiency | |
| EP2651414A1 (en) | Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer | |
| CN108938650A (en) | The application of cinobufagin | |
| CN1278731A (en) | Use of mirtazapine for treating sleep apneas | |
| KR20150011379A (en) | Methods and compositions for administration of oxybutynin | |
| CN1105236A (en) | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof | |
| CN101380461A (en) | Efficient thymosin enteric-coated tablets and thymosin for injection | |
| CN101982174A (en) | Formula of compound medicine preparation for relieving cough and preventing asthma and preparation method thereof | |
| CN109820851A (en) | Application of regorafenib hydrate in the preparation of medicaments for the treatment of pulmonary fibrosis | |
| CN1289085C (en) | Nasal spray agent | |
| JPS624229A (en) | Analgesic and antiinflammatory medicine | |
| CN101612154A (en) | Contain the compositions of pivampicillin and preparation method, purposes | |
| US11793852B2 (en) | Application of Longhu Rendan in preparing medicament for preventing and/or treating liver fibrosis | |
| CN115350194A (en) | A kind of drug combination and its application | |
| CN101474191B (en) | Pharmaceutical composition for treating asthma and chronic obstructive pulmonary disease | |
| CN113350325A (en) | Application of dianthrone compound in preparation of antitumor drugs | |
| Storms | Patient compliance with bronchodilator therapy in asthma | |
| US20250064876A1 (en) | Nebulized inhalation liquid for relieving rhinitis and preparation method thereof, and nebulizer | |
| CN103800341A (en) | Combined medicine for preventing and treating tumors | |
| CN1332664C (en) | Snuff |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication |